1. Home
  2. RNAZ vs SPHL Comparison

RNAZ vs SPHL Comparison

Compare RNAZ & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNAZ
  • SPHL
  • Stock Information
  • Founded
  • RNAZ 2016
  • SPHL 2002
  • Country
  • RNAZ United States
  • SPHL Singapore
  • Employees
  • RNAZ N/A
  • SPHL N/A
  • Industry
  • RNAZ Biotechnology: Pharmaceutical Preparations
  • SPHL Homebuilding
  • Sector
  • RNAZ Health Care
  • SPHL Consumer Discretionary
  • Exchange
  • RNAZ Nasdaq
  • SPHL Nasdaq
  • Market Cap
  • RNAZ 6.1M
  • SPHL 4.9M
  • IPO Year
  • RNAZ 2021
  • SPHL 2024
  • Fundamental
  • Price
  • RNAZ $11.36
  • SPHL $0.49
  • Analyst Decision
  • RNAZ Strong Buy
  • SPHL
  • Analyst Count
  • RNAZ 1
  • SPHL 0
  • Target Price
  • RNAZ $280.00
  • SPHL N/A
  • AVG Volume (30 Days)
  • RNAZ 10.7K
  • SPHL 2.8M
  • Earning Date
  • RNAZ 11-13-2025
  • SPHL 01-01-0001
  • Dividend Yield
  • RNAZ N/A
  • SPHL N/A
  • EPS Growth
  • RNAZ N/A
  • SPHL N/A
  • EPS
  • RNAZ N/A
  • SPHL N/A
  • Revenue
  • RNAZ N/A
  • SPHL $6,456,601.00
  • Revenue This Year
  • RNAZ N/A
  • SPHL N/A
  • Revenue Next Year
  • RNAZ N/A
  • SPHL N/A
  • P/E Ratio
  • RNAZ N/A
  • SPHL N/A
  • Revenue Growth
  • RNAZ N/A
  • SPHL N/A
  • 52 Week Low
  • RNAZ $6.15
  • SPHL $0.35
  • 52 Week High
  • RNAZ $739.20
  • SPHL $7.80
  • Technical
  • Relative Strength Index (RSI)
  • RNAZ 56.35
  • SPHL 50.03
  • Support Level
  • RNAZ $10.67
  • SPHL $0.44
  • Resistance Level
  • RNAZ $11.45
  • SPHL $0.87
  • Average True Range (ATR)
  • RNAZ 0.61
  • SPHL 0.08
  • MACD
  • RNAZ 0.10
  • SPHL 0.01
  • Stochastic Oscillator
  • RNAZ 83.81
  • SPHL 23.87

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: